Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLA Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation (HIGHT)
NCT06809699Phase 1Recruiting
- Start
- Aug 2022
- Primary completion
- Oct 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic hematopoietic stem cells in hematological malignancies. Primary endpoint: Overall Survival at 1 year. Started Aug 2022; status: recruiting.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
hematological malignancies
Beyond the preview
Go deeper on NCT06809699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06809699.